Dishman Carbogen Amcis Limited has announced that its board of directors will convene on December 27 to discuss funding arrangements through Non-Convertible Debentures (NCDs). This scheduled meeting represents an important corporate governance milestone for the pharmaceutical company as it explores debt financing options.

Board Meeting Details

The upcoming board meeting will focus specifically on evaluating funding strategies through NCDs, which are debt instruments that cannot be converted into equity shares. This financing mechanism allows companies to raise capital while maintaining their existing equity structure.

Significance of NCD Funding

Non-Convertible Debentures serve as an alternative financing tool for companies seeking to raise capital without diluting existing shareholding. For pharmaceutical companies like Dishman Carbogen Amcis, such funding mechanisms can provide the necessary resources for business operations, research and development activities, or expansion plans.

Corporate Governance Process

The scheduled board meeting demonstrates the company's adherence to proper corporate governance procedures. By convening the board to discuss funding options, Dishman Carbogen Amcis ensures that all financing decisions undergo appropriate evaluation and approval processes before implementation.

This development will be closely watched by investors and stakeholders as the company moves forward with its capital structure planning and funding strategy decisions.

Dishman Carbogen Amcis Limited has announced a significant financial development for its subsidiary, CARBOGEN AMCIS Holding AG. The Swiss-based subsidiary has successfully refinanced its syndicated credit facilities, resulting in a substantial increase in its credit capacity.

Key Highlights of the Refinancing

• Additional Credit: The refinancing has added CHF 40.00 million in extra credit capacity.
• Accordion Feature: An additional CHF 30.00 million option is available through an accordion feature.
• Total Credit Capacity: Following this refinancing, the company's total credit capacity now stands at:
  • CHF 162.24 million
  • EUR 50.00 million

Strategic Implications

This refinancing marks a significant step in supporting CARBOGEN AMCIS's future growth strategy. The company plans to leverage this enhanced credit facility to execute its vision-based strategy, focusing on several key areas:

1. Innovation: Advancing areas such as continuous flow chemistry and drug conjugation.
2. Digital Transformation: Emphasis on artificial intelligence to drive growth.
3. Efficiency: Improving operational processes across the organization.
4. Environmental and Safety Initiatives: Strengthening the company's commitment to sustainability and safety standards.

Management Perspective

Harshil Dalal, Global Chief Financial Officer, stated, "The successful refinancing and enhancement of the syndicated credit facilities provides access to an additional CHF 40 million, with an accordion feature enabling a further CHF 30 million. This marks a significant step in supporting the company's future growth."

Arpit Vyas, Global Managing Director, added, "Our vision is to make significant advances in areas such as continuous flow chemistry, drug conjugation, and digital transformation, with a keen focus on artificial intelligence — all of which will enable the company to continue its organic growth."

Banking Relationships

The transaction was led by UBS Switzerland AG, with participation from several leading Swiss financial institutions. This successful refinancing reflects the strength of CARBOGEN AMCIS's long-term relationships with its banking partners and their confidence in the Group's business strategy and future growth trajectory.

Future Outlook

Stephan Fritschi, CEO of CARBOGEN AMCIS, emphasized the importance of this refinancing for the company's growth journey. He stated, "It demonstrates the confidence our banking partners have in our long-term strategy and strengthens our ability to invest in the technologies and infrastructure that will support our customers' most advanced development programmes."

The company plans to focus on broadening its technological capabilities across its global organization, positioning CARBOGEN AMCIS at the forefront of innovation in the pharmaceutical industry.

This refinancing deal underscores Dishman Carbogen Amcis Limited's commitment to strengthening its financial position and supporting its long-term growth strategy in the pharmaceutical outsourcing market.